رکورد قبلیرکورد بعدی

" Dose-finding designs for early-phase cancer clinical trials : "


Document Type : BL
Record Number : 884031
Main Entry : Daimon, Takashi
Title & Author : Dose-finding designs for early-phase cancer clinical trials : : a brief guidebook to theory and practice /\ Takashi Daimon, Akihiro Hirakawa, Shigeyuki Matsui.
Publication Statement : Tokyo, Japan :: Springer,, [2019]
Series Statement : SpringerBriefs in statistics: JSS Research Series in statistics
Page. NO : 1 online resource
ISBN : 4431555854
: : 9784431555858
: 9784431555841
Bibliographies/Indexes : Includes bibliographical references.
Contents : 1. Introduction -- 2. Dose Finding in Early Phase Clinical Trials -- 3. Rule -- Based Designs -- 4. Continual Reassessment Method Designs -- 5. Escalation with Overdose Control Designs -- 6. Decision -- Theoretic Designs -- 7. Complex Designs.
Abstract : This book provides a comprehensive introduction to statistical methods for designing early phase dose-finding clinical trials. It will serve as a textbook or handbook for graduate students and practitioners in biostatistics and clinical investigators who are involved in designing, conducting, monitoring, and analyzing dose-finding trials. The book will also provide an overview of advanced topics and discussions in this field for the benefit of researchers in biostatistics and statistical science. Beginning with backgrounds and fundamental notions on dose finding in early phase clinical trials, the book then provides traditional and recent dose-finding designs of phase I trials for, e.g., cytotoxic agents in oncology, to evaluate toxicity outcome. Included are rule-based and model-based designs, such as 3 + 3 designs, accelerated titration designs, toxicity probability interval designs, continual reassessment method and related designs, and escalation overdose control designs. This book also covers more complex and updated dose-finding designs of phase I-II and I/II trials for cytotoxic agents, and cytostatic agents, focusing on both toxicity and efficacy outcomes, such as designs with covariates and drug combinations, maximum tolerated dose-schedule finding designs, and so on.
Subject : Antineoplastic agents.
Subject : Cancer-- Chemotherapy.
Subject : Drugs-- Dosage forms.
Subject : Antineoplastic agents.
Subject : Cancer-- Chemotherapy.
Subject : Drugs-- Dosage forms.
Dewey Classification : ‭519.5‬
: ‭615.7/98‬
LC Classification : ‭RC271.C5‬‭D35 2019‬
Added Entry : Hirakawa, Akihiro
: Matsui, Shigeyuki
کپی لینک

پیشنهاد خرید
پیوستها
Search result is zero
نظرسنجی
نظرسنجی منابع دیجیتال

1 - آیا از کیفیت منابع دیجیتال راضی هستید؟